Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany: First results from the prospective German Registry CRISP (AIO-TRK-0315).

e21236Background: Treatment in non-small cell lung cancer is quickly evolving and new agents make it to the routine practice at a rapid pace. It is of high interest to patients (pts), physicians and reimbursement institutions to investigate how outcomes from clinical trials translate into routine practice. Methods: The prospective, national clinical research platform CRISP recruits pts in currently 144 representative cancer centres in all therapeutic sectors in Germany. More than 8000 pts will be recruited and followed until death or up to a maximum of 3 years, respectively. Data from 823 pts recruited by 89 centers by June 30th, 2017 was analysed regarding molecular testing and 1st-line targeted treatment regimens. Results: Median age was 67 years, 61% of pts were male. 12% of pts were never smokers. 79% of pts had non-squamous carcinoma (nsqc), 21% squamous carcinoma (sqc). In pts with nsqc (n = 653) molecular test rates for EGFR, ALK, and ROS-1 were 73%, 70%, and 53% respectively. In pts with sqc (n = ...